4

Biocon - India's largest biopharmaceutical company · class' anti-CD6 monoclonal antibody. It has a rich pipeline of Biosimilars and Novel Biologics at various stages of development

Download PDF Report

Upload
others
View
2
Download
0

Embed Size (px)

Citation preview

Page 1: Biocon - India's largest biopharmaceutical company · class' anti-CD6 monoclonal antibody. It has a rich pipeline of Biosimilars and Novel Biologics at various stages of development

Page 2: Biocon - India's largest biopharmaceutical company · class' anti-CD6 monoclonal antibody. It has a rich pipeline of Biosimilars and Novel Biologics at various stages of development

Page 3: Biocon - India's largest biopharmaceutical company · class' anti-CD6 monoclonal antibody. It has a rich pipeline of Biosimilars and Novel Biologics at various stages of development

Page 4: Biocon - India's largest biopharmaceutical company · class' anti-CD6 monoclonal antibody. It has a rich pipeline of Biosimilars and Novel Biologics at various stages of development

Documents

Dynamic Levels Biocon Ltd · The Biosimilars opportunity is set to expand as patents expire on leading biologics and patients demand lower priced drugs. ... Pharmaceutical Sector

Dynamic Levels Biocon Ltd · The Biosimilars opportunity is set to expand as patents expire on leading biologics and patients demand lower priced drugs. ... Pharmaceutical Sector

Documents

Documents

Biocon Biologics Presentation.pdf · Next wave of biosimilars through direct commercialization Investing in digital marketing and new technologies across the value chain Ability to

Biocon Biologics Presentation.pdf · Next wave of biosimilars through direct commercialization Investing in digital marketing and new technologies across the value chain Ability to

Documents

~rTED~ - Biocon

~rTED~ - Biocon

Documents

Biosimilars: Commercial Perspective · PDF fileBiosimilars: Commercial Perspective FTC Presentation, February 4th 2014 Aaron (Ronny) Gal, Ph.D. ... Mylan/Biocon Baxter/ Momenta Merck

Biosimilars: Commercial Perspective · PDF fileBiosimilars: Commercial Perspective FTC Presentation, February 4th 2014 Aaron (Ronny) Gal, Ph.D. ... Mylan/Biocon Baxter/ Momenta Merck

Documents

Documents

Sandozand Biocon strike global biosimilars alliance · 26January2018 Sandozand Biocon strike global biosimilars alliance COMPANYNEWS 2 Alkaloid to invest in two production sites 2

Sandozand Biocon strike global biosimilars alliance · 26January2018 Sandozand Biocon strike global biosimilars alliance COMPANYNEWS 2 Alkaloid to invest in two production sites 2

Documents

Biosimilars: Will Asia Go Big in Adoption and … · To date, China and India have approved 96 and 66 follow-on biologics respectively, ... Biocon 1978 Basalog (insulin), BIOMAb EGFR

Biosimilars: Will Asia Go Big in Adoption and … · To date, China and India have approved 96 and 66 follow-on biologics respectively, ... Biocon 1978 Basalog (insulin), BIOMAb EGFR

Documents

Biocon Limited Investor Presentation - Biocon - India's ... PPT_Nov 2017.pdf · Biocon Limited Investor Presentation November 2017 BSE: 532523 │ NSE: BIOCON │ REUTERS: BION.NS

Biocon Limited Investor Presentation - Biocon - India's ... PPT_Nov 2017.pdf · Biocon Limited Investor Presentation November 2017 BSE: 532523 │ NSE: BIOCON │ REUTERS: BION.NS

Documents

Biosimilars: European Payer Perspectives (2016)€¦ · Biosimilars: European Payer Perspectives (2016) ... Biosimilars: European Payer Perspectives. ... the European biosimilars

Biosimilars: European Payer Perspectives (2016)€¦ · Biosimilars: European Payer Perspectives (2016) ... Biosimilars: European Payer Perspectives. ... the European biosimilars

Documents

Education

Shaping the biosimilars opportunity - Weinberg Group · PDF file2• SHAPING THE BIOSIMILARS OPPORTUNITY • December 2011 IMS HEALTH ... 2Pfizer to sell biosimilar insulins in Biocon

Shaping the biosimilars opportunity - Weinberg Group · PDF file2• SHAPING THE BIOSIMILARS OPPORTUNITY • December 2011 IMS HEALTH ... 2Pfizer to sell biosimilar insulins in Biocon

Documents

37th Annual General Meeting - Biocon · PDF file2019: US$24 billion (Estimated)^ Global Biosimilars Market^ Global Biosimilars in Clinical Development* ... different autoimmune diseases

37th Annual General Meeting - Biocon · PDF file2019: US$24 billion (Estimated)^ Global Biosimilars Market^ Global Biosimilars in Clinical Development* ... different autoimmune diseases

Documents

Documents

Exploracion y Produccion CD6

Exploracion y Produccion CD6

Documents

July 28 , 2017 Biocon Research Centre Kiran Mazumdar-Shaw Presentation_2017...drug market in 2022 projected to grow to US$ 337 billion Global biosimilars market in 2020 projected to

July 28 , 2017 Biocon Research Centre Kiran Mazumdar-Shaw Presentation_2017...drug market in 2022 projected to grow to US$ 337 billion Global biosimilars market in 2020 projected to

Documents

Biosimilars Clarified - Merck Clarifies Biosimilars · • Highlight Merck’s commitment to biosimilars. 3 Biological Productsand Biosimilars. 4 What Are Biological Products? MW,

Biosimilars Clarified - Merck Clarifies Biosimilars · • Highlight Merck’s commitment to biosimilars. 3 Biological Productsand Biosimilars. 4 What Are Biological Products? MW,

Documents

Documents

Ulangan Kenaikan Kelas Cd6

Ulangan Kenaikan Kelas Cd6

Documents

AGM Corporate PPT 2005 Final - ( shri edited slide 15) - Biocon · 2017-04-28 · Generics & Biosimilars A robust backbone of Generic molecules • Statins, Immuno-suppressants, Insulin

AGM Corporate PPT 2005 Final - ( shri edited slide 15) - Biocon · 2017-04-28 · Generics & Biosimilars A robust backbone of Generic molecules • Statins, Immuno-suppressants, Insulin

Documents

Zulassung und klinische Anwendung von Biosimilars Biocon Bagalore India Flothin Ranbaxy Gurgaon India Hepanox Minova Bengaluru India Macparin Macleods Mumbai India weitere... M-Enoxaparin

Zulassung und klinische Anwendung von Biosimilars Biocon Bagalore India Flothin Ranbaxy Gurgaon India Hepanox Minova Bengaluru India Macparin Macleods Mumbai India weitere... M-Enoxaparin

Documents

Biocon (BIOCON) Rs 567 - ICICI Directcontent.icicidirect.com/mailimages/Biocon -final.pdf · Biocon India incorporated as 70:30 JV between Indian promoters & Irish company Biocon

Biocon (BIOCON) Rs 567 - ICICI Directcontent.icicidirect.com/mailimages/Biocon -final.pdf · Biocon India incorporated as 70:30 JV between Indian promoters & Irish company Biocon

Documents

INVESTOR PRESENTATION - Biocon · Aim to address a Market Opportunity of US$ 0.8 Bn China Opportunity Biologics Biosimilars & Novel Biologics 13 NOVEL ... Biocon Biologics Global

INVESTOR PRESENTATION - Biocon · Aim to address a Market Opportunity of US$ 0.8 Bn China Opportunity Biologics Biosimilars & Novel Biologics 13 NOVEL ... Biocon Biologics Global

Documents

Documents

Documents

Biosimilars the regulatory framework - EDQM · Biosimilars – the regulatory framework BIOSIMILARS: SATELLITE SESSION ... Biosimilars are not generics Authorised biosimilar is an

Biosimilars the regulatory framework - EDQM · Biosimilars – the regulatory framework BIOSIMILARS: SATELLITE SESSION ... Biosimilars are not generics Authorised biosimilar is an

Documents

Social Responsibility at Mylan · 2015-07-28 · with Natco on a generic version of Copaxone®, a multiple sclerosis treat-ment. With our partner Biocon, we are developing biosimilars

Social Responsibility at Mylan · 2015-07-28 · with Natco on a generic version of Copaxone®, a multiple sclerosis treat-ment. With our partner Biocon, we are developing biosimilars

Documents

Biocon Biologics · 2019-12-13 · Biocon Biologics India Limited, India Biocon Biologics Limited, UK Biocon Biologics Inc, USA Biocon Research Limited, India Biocon SDN BHD, Malaysia

Biocon Biologics · 2019-12-13 · Biocon Biologics India Limited, India Biocon Biologics Limited, UK Biocon Biologics Inc, USA Biocon Research Limited, India Biocon SDN BHD, Malaysia

Documents

Documents